Healthcare
The HealthCare sector is facing a wide range of major challenges driven by the need to protect current earnings (to do more with less) and grow new businesses in related areas. Industry observations include: increased need for safety data regulation prior to medicine approvals; patent expiry of branded prescription medicines, generic versions of branded drugs combined with a lack of new products is causing a significant slow-down in branded sales. The sector is also increasingly driving down costs and new models of outsourcing are emerging to address such pressures. These challenges must be addressed to enable and support safe transformation and growth.
|
Industry Issue |
How we can help |
|
Efficiency in production |
Pharmaceutical companies are increasingly looking at ways of reducing production and transportation costs by outsourcing or investing in production facilities in emerging markets. |
|
Changing demographics & dependency on healthcare |
With an ageing population dependent on medication to improve the quality of their lives, the development of new drugs to treat chronic conditions and the pressure on pharmaceuticals to provide cheaper medication; the Life Science organisations are considering more innovative business models to meet the demands of their customers, including outsourcing models. With outsourcing popular and complex solutions; strong enterprise risk management processes are needed to ensure that all inherent risks are clearly identified & understood and that proper mitigation strategies are put in place. |
|
Increasing regulatory requirements |
The Healthcare industry has more compliance requirements than any other industry and more regulation is continually issued. |
|
Protecting intellectual property |
The massive cost of developing a drug and running a trial to secure regulatory approval makes it imperative that IP is protected by appropriate patents and licenses and that these are rigorously enforced. |
|
Effective Research and Development expenditure |
Organisations are looking at different ways of reducing the time, cost and associated risks of developing drugs, hence the high emphasis on research and development or outsourcing the elements of the process thereof. |
Key Contacts
Kriba Moodley
Associate Director
Mobile: 083 327 4500
Email: kmoodley@deloitte.co.za
Thought Leadership
Material on this website is © 2013 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.